Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Finished Goods: 2021-2023

Historic Finished Goods for Apellis Pharmaceuticals (APLS) over the last 3 years, with Dec 2023 value amounting to $30.7 million.

  • Apellis Pharmaceuticals' Finished Goods rose 325.22% to $13.0 million in Q1 2024 from the same period last year, while for Mar 2024 it was $13.0 million, marking a year-over-year increase of 325.22%. This contributed to the annual value of $30.7 million for FY2023, which is 1639.18% up from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Finished Goods stood at $30.7 million for FY2023, which was up 1,639.18% from $1.8 million recorded in FY2022.
  • Apellis Pharmaceuticals' Finished Goods' 5-year high stood at $30.7 million during FY2023, with a 5-year trough of $479,000 in FY2021.
  • Over the past 3 years, Apellis Pharmaceuticals' median Finished Goods value was $1.8 million (recorded in 2022), while the average stood at $11.0 million.
  • Data for Apellis Pharmaceuticals' Finished Goods shows a peak YoY skyrocketed of 1,639.18% (in 2023) over the last 5 years.
  • Over the past 3 years, Apellis Pharmaceuticals' Finished Goods (Yearly) stood at $479,000 in 2021, then surged by 268.68% to $1.8 million in 2022, then spiked by 1,639.18% to $30.7 million in 2023.